Story Highlight
- Researchers study myostatin and follistatin for muscle health influence.
- Dr Sanjeev Goel explores gene therapy to increase follistatin production.
- Muscle strength better reflects physical health than size alone.
- Gene therapy aims for sustained follistatin expression without repeated injections.
- Further research needed to confirm gene therapy safety and effectiveness.
Full Story
Muscle loss, often seen as a natural consequence of ageing, is now the subject of extensive research aimed at understanding its biological mechanisms. Scientists are particularly interested in myostatin and follistatin, proteins that play crucial roles in muscle growth regulation. Dr Sanjeev Goel, MD, Founder and CEO of Peak Human, is investigating a novel approach involving gene therapy intended to boost the body’s follistatin production. Instead of relying on repeated injections or supplements, this method aims to provide cells genetic instructions that may stimulate prolonged follistatin expression.
Myostatin is a protein that naturally regulates skeletal muscle development, preventing excessive muscle growth, while follistatin can inhibit myostatin and other proteins that limit muscle development. This interaction has prompted research into its potential role in muscle wasting, ageing, metabolic health, and physical performance. Researchers are examining the possibility of modifying this pathway to help preserve muscle tissue and maintain physical function, especially as physical inactivity rises with age. The World Health Organization reported that in 2022, 31% of adults globally, equivalent to 1.8 billion people, did not meet recommended activity levels, a figure projected to reach 35% by 2030.
Data indicate that maintaining muscle is critical for more than physical appearance—muscle strength is linked to movement, glucose regulation, and overall balance. An analysis conducted in the United States highlighted that 25.6% of adults aged 50 to 80 met sarcopenia criteria based on grip strength, much higher than the 15.6% determined by lean mass and 13.8% by gait speed. Consequently, there is a growing emphasis on approaches that focus on both muscle composition and functional strength.
Dr Goel’s strategy utilises gene delivery systems, such as adeno-associated viruses or plasmid technology, to convey genetic instructions for follistatin production. This method contrasts with traditional treatment approaches, aiming to enable cells to autonomously produce the protein over time. Increased follistatin levels could suppress myostatin activity, consequently affecting muscle growth signals. Changes might then be evaluated through muscle mass, strength, body composition, and various physiological markers. Although comprehensive clinical studies on follistatin gene therapy are still lacking, early observational data from organizations like BioViva and Minicircle show potentially positive outcomes in humans, although safety and efficacy remain unconfirmed.
The research community aims to investigate how alterations in the myostatin-follistatin pathway influence muscle function and overall physiology. This involves a shift from merely assessing lean mass gains to evaluating a wider scope of outcomes, including strength, body composition, and metabolic indicators. Understanding these variables is essential, as muscle size does not inherently indicate quality or capability.
As gene therapy continues to evolve, its potential to unravel the complex biological pathways governing muscle maintenance and growth presents exciting prospects. Research into follistatin and myostatin could enhance knowledge about the body’s intrinsic muscle regulation systems, paving the way for new strategies to support muscle health and functional capacity during ageing. Meanwhile, traditional elements such as resistance training, nutrition, cardiovascular activity, and quality sleep continue to be vital for maintaining muscle health as people grow older.
Source: read the original report.
What this means for your site
The article does not present a workplace or public safety incident with actionable insights for safety managers, site managers, or business owners. Therefore, there are no specific lessons or improvements that can be drawn from it in relation to UK health and safety legislation or practices.
